Switch theme
Sign up to access all valuation multiples
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
1991
2.6K+
LTM Revenue $4.5B
LTM EBITDA $645M
$10.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Incyte has a last 12-month revenue (LTM) of $4.5B and a last 12-month EBITDA of $645M.
In the most recent fiscal year, Incyte achieved revenue of $4.2B and an EBITDA of $408M.
Incyte expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Incyte valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.5B | XXX | $4.2B | XXX | XXX | XXX |
| Gross Profit | $4.2B | XXX | $3.9B | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $645M | XXX | $408M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $895M | XXX | $101M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $687M | XXX | $32.6M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Incyte's stock price is $69.
Incyte has current market cap of $13.3B, and EV of $10.9B.
See Incyte trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.9B | $13.3B | XXX | XXX | XXX | XXX | $3.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Incyte has market cap of $13.3B and EV of $10.9B.
Incyte's trades at 2.6x EV/Revenue multiple, and 26.8x EV/EBITDA.
Equity research analysts estimate Incyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Incyte has a P/E ratio of 19.4x.
See valuation multiples for Incyte and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.3B | XXX | $13.3B | XXX | XXX | XXX |
| EV (current) | $10.9B | XXX | $10.9B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 17.0x | XXX | 26.8x | XXX | XXX | XXX |
| EV/EBIT | 12.2x | XXX | 108.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.4x | XXX | 407.9x | XXX | XXX | XXX |
| EV/FCF | 18.4x | XXX | 46.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIncyte's last 12 month revenue growth is 11%
Incyte's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $1.5M for the same period.
Incyte's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Incyte's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Incyte and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 111% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Incyte acquired XXX companies to date.
Last acquisition by Incyte was XXXXXXXX, XXXXX XXXXX XXXXXX . Incyte acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Incyte founded? | Incyte was founded in 1991. |
| Where is Incyte headquartered? | Incyte is headquartered in United States of America. |
| How many employees does Incyte have? | As of today, Incyte has 2.6K+ employees. |
| Who is the CEO of Incyte? | Incyte's CEO is Mr. Herve Hoppenot. |
| Is Incyte publicy listed? | Yes, Incyte is a public company listed on NAS. |
| What is the stock symbol of Incyte? | Incyte trades under INCY ticker. |
| When did Incyte go public? | Incyte went public in 1993. |
| Who are competitors of Incyte? | Similar companies to Incyte include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Incyte? | Incyte's current market cap is $13.3B |
| What is the current revenue of Incyte? | Incyte's last 12 months revenue is $4.5B. |
| What is the current revenue growth of Incyte? | Incyte revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Incyte? | Current revenue multiple of Incyte is 2.4x. |
| Is Incyte profitable? | Yes, Incyte is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Incyte? | Incyte's last 12 months EBITDA is $645M. |
| What is Incyte's EBITDA margin? | Incyte's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Incyte? | Current EBITDA multiple of Incyte is 17.0x. |
| What is the current FCF of Incyte? | Incyte's last 12 months FCF is $594M. |
| What is Incyte's FCF margin? | Incyte's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Incyte? | Current FCF multiple of Incyte is 18.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
